Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 25:5:1485420.
doi: 10.3389/fpain.2024.1485420. eCollection 2024.

Vascular and nerve biomarkers in thigh skin biopsies differentiate painful from painless diabetic peripheral neuropathy

Affiliations

Vascular and nerve biomarkers in thigh skin biopsies differentiate painful from painless diabetic peripheral neuropathy

Gordon Sloan et al. Front Pain Res (Lausanne). .

Abstract

Background: Identifying distinct mechanisms and biomarkers for painful diabetic peripheral neuropathy (DPN) is required for advancing the treatment of this major global unmet clinical need. We previously provided evidence in calf skin biopsies that disproportion between reduced sensory small nerve fibers and increased blood vessels may distinguish painful from non-painful DPN. We proposed that overexposure of the reduced nerve fibers in DPN to increased hypoxemia-induced vasculature and related algogenic factors, e.g., nerve growth factor (NGF), leads to neuropathic pain. To further investigate this proposed mechanism, we have now studied more proximal thigh skin biopsies, to see if the same disproportion between increased vasculature and decreased nerve fibers generally differentiates painful DPN from painless DPN.

Methods: A total of 28 subjects with type 2 diabetes (T2DM) and 13 healthy volunteers (HV) underwent detailed clinical and neurophysiological assessments, based on the neuropathy composite score of the lower limbs [NIS(LL)] plus 7 tests. T2DM subjects were subsequently divided into three groups: painful DPN (n = 15), painless DPN (n = 7), and no DPN (n = 6). All subjects underwent skin punch biopsy from the upper lateral thigh 20 cm below the anterior iliac spine.

Results: Skin biopsies showed decreased PGP 9.5-positive intraepidermal nerve fiber (IENF) density in both painful DPN (p < 0.0001) and painless DPN (p = 0.001). Vascular marker von Willebrand Factor (vWF) density was markedly increased in painful DPN vs. other groups, including painless DPN (p = 0.01). There was a resulting significant decrease in the ratio of intraepidermal nerve fiber density to vasculature and PGP9.5 to vWF, in painful DPN vs. painless DPN (p = 0.05). These results were similar in pattern to those observed in these HV and T2DM groups previously in distal calf biopsies; however, the increase in vWF was much higher and nerve fiber density much lower in the calf than thigh for painful DPN. Thigh skin vWF density was significantly correlated with several metabolic (waist/hip ratio, HbA1c), clinical (e.g., pain score), and neurophysiological measures.

Conclusion: This study supports our proposal that increased dermal vasculature, and its disproportionate ratio to reduced nociceptors, may help differentiate painful DPN from painless DPN. This disproportion is greater in the distal calf than the proximal thigh skin; hence, neuropathic pain in DPN is length-dependent and first localized to the distal lower limbs, mainly feet.

Keywords: IENF; biomarkers; pain; painful diabetic neuropathy; skin; type 2 diabetes; vascular; von Willebrand factor.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
(a) PGP9.5 immunoreactivity in thigh skin biopsies from the healthy volunteers and the HV, (b) painful-DPN, (c) painless-DPN, and (d) no-DPN groups. Magnification, ×40. (e) Mean ± SEM of the PGP9.5 intraepidermal nerve fibers (fibers/mm).
Figure 2
Figure 2
(a) vWF immunoreactivity in thigh skin from the healthy volunteers and the HV, (b) painful-DPN, (c) painless-DPN, and (d) no-DPN groups. Magnification ×40. (e) Image analysis of vWF subepidermal vessel immunostaining (% immunoreactivity).
Figure 3
Figure 3
Bar charts showing image analyses (mean ± SEM) of PGP9.5 IENF: vWF ratios in thigh skin from the healthy volunteers and the HV, painful-DPN, painless-DPN, and no-DPN groups.

References

    1. Sloan G, Selvarajah D, Tesfaye S. Pathogenesis, diagnosis and clinical management of diabetic sensorimotor peripheral neuropathy. Nat Rev Endocrinol. (2021) 17:400–20. 10.1038/s41574-021-00496-z - DOI - PubMed
    1. Galer BS, Gianas A, Jensen MP. Painful diabetic polyneuropathy: epidemiology, pain description, and quality of life. Diabetes Res Clin Pract. (2000) 47:123–8. 10.1016/s0168-8227(99)00112-6 - DOI - PubMed
    1. Abbott CA, Malik RA, van Ross ERE, Kulkarni J, Boulton AJM. Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the U.K. Diabetes Care. (2011) 34:2220–4. 10.2337/dc11-1108 - DOI - PMC - PubMed
    1. Tölle T, Xu X, Sadosky AB. Painful diabetic neuropathy: a cross-sectional survey of health state impairment and treatment patterns. J Diabetes Complicat. (2006) 20:26–33. 10.1016/j.jdiacomp.2005.09.007 - DOI - PubMed
    1. Selvarajah D, Cash T, Sankar A, Thomas L, Davies J, Cachia E, et al. The contributors of emotional distress in painful diabetic neuropathy. Diab Vasc Dis Res. (2014) 11:218–25. 10.1177/1479164114522135 - DOI - PubMed

LinkOut - more resources